BMY Q2 2019 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q2 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$6.3B+10.0% YoY

Gross Profit

$4.4B70.2% margin

Operating Income

$2.0B32.2% margin

Net Income

$1.4B22.8% margin

EPS (Diluted)

$0.87

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

$2.1B

Free Cash Flow

$1.9B

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$55.2B

Total Liabilities

$39.0B

Stockholders' Equity

$16.0B

Cash & Equivalents

$28.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6.3B	$5.7B	+10.0%
Gross Profit	$4.4B	$4.1B	+7.2%
Operating Income	$2.0B	$559M	+261.0%
Net Income	$1.4B	$373M	+283.9%

Revenue Segments

Eliquis

$2.0B33%

Opdivo

$1.8B29%

Orencia

$778M12%

Sprycel

$544M9%

Mature Products And All Other

$481M8%

Yervoy

$367M6%

Baraclude

$147M2%

Empliciti

$91M1%

Geographic Segments

UNITED STATES

$3.7B58%

Europe

$1.5B24%

Rest Of World

$988M16%

Other Region

$127M2%